Vyne Therapeutics INC 8-K filings

Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.) announced the completion of its merger with VYNE Therapeutics, securing approximately $200 million in financing and providing an estimated cash runway into 2028, while advancing its lead drug candidate YB-101 for autoimmune thyroid diseases.

Yarrow Bioscience, Inc. announced an exchange of common stock for pre-funded warrants, impacting outstanding share counts and ownership limitations.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) announced the closing of its merger with Yarrow Bioscience, Inc. and the commencement of dosing in a Phase 2a/2b trial for YB-101, a potential treatment for Graves' disease and thyroid eye disease.

VYNE Therapeutics is implementing a 1-for-50 reverse stock split and a special cash dividend in preparation for its merger with Yarrow Bioscience, Inc.

VYNE Therapeutics and Yarrow Bioscience have released an investor presentation detailing their proposed merger and Yarrow's lead drug candidate, YB-101, for Graves' Disease and Thyroid Eye Disease.

VYNE Therapeutics announced a special cash dividend of an estimated $16.5 million, or $0.38 per share, in connection with its proposed merger with Yarrow Bioscience.

Yarrow Bioscience unveils its lead drug candidate, YB-101, an anti-TSHR antibody, highlighting its potential in Graves' Disease and Thyroid Eye Disease, with Phase 2 trials planned and significant funding secured.

VYNE Therapeutics Inc. has amended its merger agreement with Yarrow Bioscience, Inc. to introduce pre-funded warrants for Yarrow shareholders and clarify dividend distribution.

VYNE Therapeutics and Yarrow Bioscience announce an all-stock merger, creating a combined company focused on autoimmune thyroid disease therapies with $200M in new financing.

VYNE Therapeutics Inc. announced the results of its 2025 annual meeting, where stockholders elected two Class I directors, ratified Baker Tilly US, LLP as its independent auditor, and approved executive compensation.

VYNE Therapeutics announced its third-quarter 2025 financial results, highlighted by an ongoing strategic review and progress on VYN202's clinical hold resolution.

VYNE Therapeutics Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

VYNE Therapeutics announced its second quarter 2025 financial results, highlighted by cost reductions extending its cash runway into the first half of 2027 and updates on its clinical pipeline.

VYNE Therapeutics announced disappointing topline results from its Phase 2b trial of Repibresib gel for nonsegmental vitiligo, missing primary and key secondary endpoints, leading to trial termination and a search for an external partner.

VYNE Therapeutics announces its first quarter 2025 financial results and provides a business update, highlighting the expected top-line results from the Phase 2b trial of repibresib gel for vitiligo in mid-2025 and a cash runway into the second half of 2026.

VYNE Therapeutics announces its 2024 financial results and provides a business update, highlighting upcoming data readouts for repibresib gel and VYN202 in 2025 and a cash runway into the second half of 2026.

VYNE Therapeutics has updated its corporate presentation to include Phase 1a data for VYN202 and provide updates on its pipeline programs.

VYNE Therapeutics reports positive top-line data from its Phase 1a trial of VYN202, a novel BD2-selective BET inhibitor, showing a favorable safety profile and robust pharmacodynamic activity.

VYNE Therapeutics stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares available for issuance and modifying share recycling rules.

VYNE Therapeutics announced positive progress in its clinical trials for VYN201 and VYN202, along with its financial results for the third quarter of 2024.

VYNE Therapeutics reports positive initial safety and efficacy data from its Phase 1a trial of VYN202, a novel BD2-selective BET inhibitor.

VYNE Therapeutics reported its Q2 2024 financial results and provided updates on its clinical programs, including the initiation of Phase 2b and Phase 1a trials for VYN201 and VYN202, respectively.

VYNE Therapeutics announced its first quarter 2024 financial results and provided a business update, highlighting progress in its VYN201 and VYN202 clinical programs.

VYNE Therapeutics announced its 2023 fourth quarter and year-end financial results, highlighting clinical advancements for VYN201 and VYN202 and a strong cash position.